Cargando…
Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis
BACKGROUND: Worse prognosis of endometrial cancers (EC) in tamoxifen‐treated women compared to non‐tamoxifen‐treated women been proposed. The relationship between tamoxifen treatment of breast cancer (BC) and the risk of EC is controversial and there is no agreement between publication results on th...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075294/ https://www.ncbi.nlm.nih.gov/pubmed/36916539 http://dx.doi.org/10.1002/cnr2.1806 |
_version_ | 1785019893723168768 |
---|---|
author | Ghanavati, Matin Khorshidi, Yasaman Shadnoush, Mahdi Akbari, Mohammad Esmaeil Ardehali, Seyed Hossein Chavarri‐Guerra, Yanin Akbari, Atieh Barragan‐Carrillo, Regina Amin Amlashi, Manoochehr Javid, Zeinab Rahmani, Jamal |
author_facet | Ghanavati, Matin Khorshidi, Yasaman Shadnoush, Mahdi Akbari, Mohammad Esmaeil Ardehali, Seyed Hossein Chavarri‐Guerra, Yanin Akbari, Atieh Barragan‐Carrillo, Regina Amin Amlashi, Manoochehr Javid, Zeinab Rahmani, Jamal |
author_sort | Ghanavati, Matin |
collection | PubMed |
description | BACKGROUND: Worse prognosis of endometrial cancers (EC) in tamoxifen‐treated women compared to non‐tamoxifen‐treated women been proposed. The relationship between tamoxifen treatment of breast cancer (BC) and the risk of EC is controversial and there is no agreement between publication results on this issue (the answer to all comments provided in the page 2 of manuscript). The aim of this study is investigation the association between tamoxifen treatment and the risk of EC in patients with BC. METHODS AND RESULTS: We conducted a comprehensive search with related keywords in MEDLINE/PubMed, SCOPUS, and Web of Science databases until April 16, 2022. Random‐effects model (DerSimonian and Laird) was used to pool risk ratios (RRs) with 95% confidence intervals (CIs) of EC. Dose, cumulative dose, and duration‐response analysis were performed in linear and non‐linear states. Twenty‐six studies reported a relation between tamoxifen treatment and risk of EC in patients with BC. Results showed a direct relationship between tamoxifen use and EC (RR: 2.03, 95% CI: 1.68–2.45; I2:76%). By increase the age of participants, the risk of EC was decrease (coef = −.0206), although this was not statistically significant (p = .37). Linear dose–response model indicated a direct significant association between dose and duration use of tamoxifen and EC (dose: exe(b) = 1.019, p = .001; duration: exe(b) = 1.014, p = .001). Non‐linear dose–response analysis confirmed linear analysis. CONCLUSION: This study highlights that tamoxifen use is a significant risk factor related to the incidence of EC in patients with BC. |
format | Online Article Text |
id | pubmed-10075294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100752942023-04-06 Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis Ghanavati, Matin Khorshidi, Yasaman Shadnoush, Mahdi Akbari, Mohammad Esmaeil Ardehali, Seyed Hossein Chavarri‐Guerra, Yanin Akbari, Atieh Barragan‐Carrillo, Regina Amin Amlashi, Manoochehr Javid, Zeinab Rahmani, Jamal Cancer Rep (Hoboken) Review BACKGROUND: Worse prognosis of endometrial cancers (EC) in tamoxifen‐treated women compared to non‐tamoxifen‐treated women been proposed. The relationship between tamoxifen treatment of breast cancer (BC) and the risk of EC is controversial and there is no agreement between publication results on this issue (the answer to all comments provided in the page 2 of manuscript). The aim of this study is investigation the association between tamoxifen treatment and the risk of EC in patients with BC. METHODS AND RESULTS: We conducted a comprehensive search with related keywords in MEDLINE/PubMed, SCOPUS, and Web of Science databases until April 16, 2022. Random‐effects model (DerSimonian and Laird) was used to pool risk ratios (RRs) with 95% confidence intervals (CIs) of EC. Dose, cumulative dose, and duration‐response analysis were performed in linear and non‐linear states. Twenty‐six studies reported a relation between tamoxifen treatment and risk of EC in patients with BC. Results showed a direct relationship between tamoxifen use and EC (RR: 2.03, 95% CI: 1.68–2.45; I2:76%). By increase the age of participants, the risk of EC was decrease (coef = −.0206), although this was not statistically significant (p = .37). Linear dose–response model indicated a direct significant association between dose and duration use of tamoxifen and EC (dose: exe(b) = 1.019, p = .001; duration: exe(b) = 1.014, p = .001). Non‐linear dose–response analysis confirmed linear analysis. CONCLUSION: This study highlights that tamoxifen use is a significant risk factor related to the incidence of EC in patients with BC. John Wiley and Sons Inc. 2023-03-14 /pmc/articles/PMC10075294/ /pubmed/36916539 http://dx.doi.org/10.1002/cnr2.1806 Text en © 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Ghanavati, Matin Khorshidi, Yasaman Shadnoush, Mahdi Akbari, Mohammad Esmaeil Ardehali, Seyed Hossein Chavarri‐Guerra, Yanin Akbari, Atieh Barragan‐Carrillo, Regina Amin Amlashi, Manoochehr Javid, Zeinab Rahmani, Jamal Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis |
title | Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis |
title_full | Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis |
title_fullStr | Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis |
title_full_unstemmed | Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis |
title_short | Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis |
title_sort | tamoxifen use and risk of endometrial cancer in breast cancer patients: a systematic review and dose–response meta‐analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075294/ https://www.ncbi.nlm.nih.gov/pubmed/36916539 http://dx.doi.org/10.1002/cnr2.1806 |
work_keys_str_mv | AT ghanavatimatin tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis AT khorshidiyasaman tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis AT shadnoushmahdi tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis AT akbarimohammadesmaeil tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis AT ardehaliseyedhossein tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis AT chavarriguerrayanin tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis AT akbariatieh tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis AT barragancarrilloregina tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis AT aminamlashimanoochehr tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis AT javidzeinab tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis AT rahmanijamal tamoxifenuseandriskofendometrialcancerinbreastcancerpatientsasystematicreviewanddoseresponsemetaanalysis |